Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis
- (no title)
- (no title)
- Elenagen helps women with ovarian cancer live 1 year longer
- (no title)
- Blood test helps predict myeloma relapse risk without biopsy
- The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
- MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
- Trial testing cell therapy for hard-to-treat AML now full in both countries
- Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review